Kaitai Capital

Sheng Sheng Biology is a biotechnology company that provides medical research and experimental development services.

Xinyue Ltd. is an online audio and video production platform based in Shanghai, China, founded in 2017. The platform offers a range of tools designed to enhance the video production process, including features for reviewing, automatic sorting, project collaboration, sharing, and video comparison. It supports multi-platform previewing and facilitates convenient review comments and video storage. Additionally, Xinyue provides an online mobile application that allows users to synchronize video data captured by cameras with a cloud server in real-time. This integration of digital cloud technology streamlines video management, enabling producers to efficiently manage, collaborate on, and share their video projects.

TechnoDerma Medicines is a private clinical-stage biopharmaceutical company dedicated to developing innovative therapies for various skin diseases. Its research and development efforts focus on small molecular drugs aimed at treating conditions such as androgenetic alopecia, atopic dermatitis, psoriasis, lupus erythematosus, and scars. The company's goal is to provide patients with safe and effective treatment options, addressing unmet medical needs in the dermatological field.

Minova Pharma is engaged in the development of innovative small molecule medications and complex formulations, primarily in the realms of spirituality and medical aesthetics. The company is dedicated to researching and creating new drugs aimed at enhancing both spiritual well-being and aesthetic outcomes. Currently, Minova Pharma has one product in clinical research within the medical aesthetics sector, while several other products are in pre-clinical research stages. This focus on novel therapeutics aims to address patients' needs and improve their quality of life.

Phanes Therapeutics, Inc. is a biotechnology company based in San Diego, California, established in 2016. The company specializes in drug discovery and early development, primarily in the fields of immuno-oncology and eye diseases. Phanes Therapeutics is developing a range of therapeutic molecules, including a monoclonal antibody aimed at treating solid tumors, as well as therapies for age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Additionally, the company is working on bispecific antibodies targeting small cell lung cancer. Through its extensive scientific expertise and innovative approaches, Phanes Therapeutics aims to create effective treatment options that enhance patient care and improve outcomes for those suffering from various conditions.

Avirmax is a Delaware-based corporation located in Hayward, California, dedicated to the research, development, and manufacturing of adeno-associated viruses. The company focuses on creating innovative technologies aimed at improving viral vector generation, addressing prevalent challenges in this field. Avirmax specializes in developing gene therapy drugs specifically targeting chronic eye diseases, utilizing proprietary protein therapeutics and advanced manufacturing techniques. Its goal is to provide patients with effective, safe, and long-lasting biotherapeutics that are both affordable and accessible.

Genemagic Biosciences is a biotechnology company that develops regenerative medicines and therapies for neurological and ocular diseases.

Anji Pharmaceuticals is focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide.

Atom Bioscience is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory and metabolic diseases. The company concentrates on addressing conditions such as chronic gout, non-alcoholic steatohepatitis, diabetes, and colon cancers. By targeting the underlying mechanisms of metabolism and inflammation, Atom Bioscience aims to provide patients with more effective treatment options for these complex health issues.

Nafi Pharmaceuticals develops novel medications for central nervous system illnesses.

Huaboron Neutron is a biotechnology company that develops boron drugs and boron neutron capture therapy devices for the diagnosis of malignant cancers.

Levinthal operates as an AI-driven protein design platform, specializing in the development of artificial intelligence algorithms and experimental process technology. The company focuses on improving the industrial production of biological molecules and microbes, catering to sectors such as synthetic biology, food, feed, cosmetics, and environmental protection. By leveraging its expertise, Levinthal aims to enhance the stability and efficiency of enzymes, thereby providing valuable technical services that support advancements in food safety and medical care.

Chiplego focuses on embedded high-performance computing systems that assist in the creation of a mobile digital world and a better travel and life experience for everyone.

Xihu Xinchen is a technology company focusing on the research and development of artificial intelligence services.

ONL Therapeutics is a biopharmaceutical company focused on developing innovative therapeutics to protect and improve vision in patients with retinal diseases and conditions. Founded in 2006 and headquartered in Ann Arbor, Michigan, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway. Its drug programs aim to safeguard photoreceptors, thereby enhancing outcomes for patients undergoing surgeries related to retinal detachment and other serious vision-threatening issues. Through its research and development efforts, ONL Therapeutics seeks to provide effective solutions for preserving sight and improving the quality of life for individuals affected by these conditions.

Yuanqi Pharmaceutical is a biotechnology company that offers custom synthesis services for compounds, molecules, and raw materials.

Beijing ICAN Technology Co. Ltd. is a leading weather station operation company that specializes in developing a big data, information, and analytics platform tailored for agriculture. Founded in 2016, the company offers comprehensive services that integrate weather, soil data, local crop management practices, and pest information. ICAN Technology's systems include a robust database, statistical software, and an Internet of Things framework, facilitating real-time data collection through agricultural weather stations and field imaging. The company is also involved in seed production and breeding services, leveraging expertise from its founders and research center, which focuses on advanced plant growth and weather forecasting models. With over 100 private weather stations across China, ICAN Technology serves major seed companies, employing a unique business model aimed at profitability.

Compass Biotechnology (Xinjiang) is a biotechnology developer focused on genomics applications of industry side.

Rgenta Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of RNA-targeting medicines with a primary focus on oncology and neurological disorders. Founded in 2018, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This platform enables the design of small-molecule compounds that modulate interactions among the spliceosome, regulatory proteins, and RNAs. By unlocking the therapeutic potential of previously undruggable targets, Rgenta aims to create oral, small-molecule therapies that address critical needs in human disease treatment, particularly in the realm of cancer.

Primelink Bio is a biotechnology firm focused on advancing drug delivery systems, particularly through the development of antibody-drug conjugates (ADCs). The company employs bioconjugation technology to create a diverse library of ADC drug candidates using a flexible and modular platform. This approach allows Primelink Bio to identify optimal drug compositions tailored to specific targets, enhancing treatment options for cancer patients. By innovating in the field of drug delivery, Primelink Bio aims to improve the efficacy of cancer therapies.

Ruixun Biotech is a healthcare company that provides biotechnology. Ruixun Biotech combines microfluidics, optics, precision instruments, electronic engineering, and biochemical technologies to create upstream equipment and consumables for molecular diagnosis and genetic testing. They released a number of products, including the digital PCR apparatus DropX-2000 and more than 50 different RUO detection kits.

Lupeng Pharmaceutical is a clinical-stage company dedicated to the discovery and development of innovative therapies for cancer and other serious health conditions. The company specializes in researching and developing novel molecular drugs aimed at treating various diseases, including tumors and hepatitis B. By focusing on innovative drug development, Lupeng Pharmaceutical aims to provide effective treatment options for patients suffering from these challenging health issues.

Realibox is a provider of an advanced online 3D digital design and collaborative cloud platform aimed at global consumer manufacturing companies, including those in electronics, daily necessities, and vehicles. The platform serves as a comprehensive solution for industrial product designers, facilitating 3D design collaboration and management. By integrating 3D design data, Realibox enhances teamwork and streamlines the product development process, ultimately reducing the product launch cycle. This enables companies to accelerate product innovation and achieve their digital transformation goals while improving efficiency and reducing costs.

Paradromics, Inc. is focused on developing advanced brain-machine interfaces aimed at enhancing communication between the brain and external devices, particularly for individuals with neurodegenerative diseases. The company specializes in creating implantable systems that facilitate neural data decoding, allowing complex brain signals to be translated into data streams suitable for various neural prostheses. Paradromics is dedicated to providing high data-rate brain-computer interface technology that supports bidirectional data transmission, enabling patients to regain functionality lost due to neurological conditions. Founded in 2015, the company is headquartered in Austin, Texas.

Worg Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for allergies and other diseases with significant unmet medical needs. The company is constructing a robust pipeline targeting allergy and autoimmune disorders through two technology platforms, PCFiT and Apitope, leveraging both internal development and strategic collaborations. Additionally, Worg is advancing a platform for molecular allergy diagnosis, enhancing its capabilities in addressing allergy-related health issues. Through its flexible business models, Worg Pharmaceuticals aims to accelerate the development of effective immunotherapies and contribute to improved patient outcomes in the field of allergy and autoimmune diseases.

Biovision Pharma is a biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT) integrated with visual diagnosis and treatment.

Biovision Pharma is a biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT) integrated with visual diagnosis and treatment.

Aoquan is a biopharmaceutical company that provides research and development, production, and industrialization of innovative drugs.

GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

Wangfanxin is an enterprise digital transformation solution provider. Based on the application of process mining, it mainly provides services such as process visualization, process variation, and analysis of process data.

Apache DolphinScheduler is a distributed and extensible workflow scheduler platform with powerful DAG visual interfaces.

Yiwise is an artificial intelligence company focused on research and development in the field of Natural Language Processing (NLP) and human-computer interaction. The company specializes in technologies that enhance dialogue interactions, enabling enterprises to effectively engage with large member bases and streamline operations. Yiwise's offerings include advanced voice intelligence solutions that improve telemarketing and customer service efficiency through autonomous speech configuration and real-time multi-party communication. By leveraging deep learning and sophisticated speech processing algorithms, Yiwise provides tailored AI capabilities and intelligent services to optimize the human-computer interaction experience for its clients.

Worktile is a software-as-a-service (SaaS) platform designed to enhance enterprise work efficiency through office collaboration tools. It provides a comprehensive solution for task management, communication, and document sharing, thereby addressing the challenges of fragmented communication and management that can impede productivity. The platform enables employees to effectively collaborate by linking tasks, sharing files, and managing reports, which fosters improved internal communication. Worktile’s user-friendly interface facilitates a seamless experience, making it suitable for various work scenarios and contributing to overall organizational effectiveness.

Pleryon Therapeutics is a company focused on advancing drug delivery systems to enhance the standard of living globally. By leveraging its proprietary platform, Pleryon develops innovative drug delivery technologies that cater to a wide range of molecules and therapeutic areas. This approach not only facilitates new drug discovery but also aims to provide patients with access to effective treatments across various medical conditions. The company's commitment to improving healthcare outcomes is reflected in its dedication to creating advanced solutions in drug delivery.

Ke Ning Bio is an ophthalmic pharmaceutical manufacturer dedicated to developing ophthalmic drugs.

GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

TaoCloud specializes in intelligent software-defined storage solutions tailored for enterprise-level customers. The company has made significant long-term investments in research and development, which enhance its product offerings in software-defined storage (SDS) technology. TaoCloud has progressed from its first-generation capacity SDS 1.0 to the advanced performance-extreme all-flash SDS 2.0, establishing strong technological barriers and competitiveness in the market. Its products facilitate distributed data storage and management, incorporating features that streamline data handling and improve efficiency for enterprises.

Juncell Therapeutics focuses on developing innovative therapies and pharmaceutical drugs specifically for tumor treatment. The company specializes in tumor cell therapy, offering solutions to isolate tumor-infiltrating lymphocytes (TILs) from tumor tissues. These TILs are subsequently developed outside the human body and re-injected into patients, allowing for targeted treatment of tumors. This approach aims to enhance the effectiveness of cancer therapies while minimizing side effects, ultimately improving patient outcomes in the fight against cancer.

Junsai Shengwu developes therapies for new solid tumor cell.

Atom Bioscience is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory and metabolic diseases. The company concentrates on addressing conditions such as chronic gout, non-alcoholic steatohepatitis, diabetes, and colon cancers. By targeting the underlying mechanisms of metabolism and inflammation, Atom Bioscience aims to provide patients with more effective treatment options for these complex health issues.

Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases.

Ceram Pharmaceuticals is a biotech firm that uses epigenetics to carry out R&D of drugs and diagnostic treatments for cancer and diseases.

Juwei Yuanchuang is a biotechnology company that produces fermentation raw materials out of agricultural and animal husbandry wastes.

Dashi Pharmaceuticals is a pharmaceutical company that provides anti-body drug research and development and molecular engineering solutions.

LifeFoundry, Inc. is a research and development firm that specializes in synthetic biology and automated bio-manufacturing. Founded in 2016 and headquartered in Champaign, Illinois, with additional offices in China and the USA, the company focuses on assisting biotech firms, particularly in the fermentation sector, in developing extensive collections of bacteria with targeted mutations. By leveraging advanced robotics and synthetic biology techniques, LifeFoundry provides high-throughput and flexible solutions for engineering biological systems, catering to the practical needs of the industry.

DigiCodon is an IT company that offers hardware and software integration, hierarchical storage architecture, and data integration solutions.

West Lake Xinchen is an AI psychological service technology company, committed to creating an inclusive, scientific, intelligent and professional AI psychological service platform, and insisting on providing customers with scientific and rigorous psychological services.

Xihu Xinchen is a technology company focusing on the research and development of artificial intelligence services.

Tianti Biotherapeutics is a biotechnology company focused on the research and development of antibody drugs. It utilizes its proprietary Ablink platform, which facilitates extensive screening and the construction of libraries containing tens of millions of single B cells. This innovative approach enhances the efficiency of antibody development, allowing drug companies to improve the quality and effectiveness of new therapeutic antibodies. Through its advanced drug discovery capabilities, Tianti Biotherapeutics aims to contribute significantly to the field of biopharmaceuticals.

Ring Code Bio is a biomedical company that develops nucleic acid drugs based on a unique circular RNA technology platform.

CirCode Bio is an innovative biotechnology company focusing on the development of circular RNA nucleic acid drugs.

Rongzhi Information is a robotic process automation software developer focusing on the application of AI technology in the enterprise.

Zhinian Technology is a big data solution provider that develops a system with a memory-based distributed database & computing framework. The system also provides a complete set of big data process services including vector-based programming language, data query, cleaning, analysis, modeling, and visualization.

Redesign Science is a computational chemistry company focused on advancing early-stage small molecule drug discovery. By utilizing first-principles physics and artificial intelligence, the company simulates protein targets at the atomic level, uncovering subtle drug opportunities that traditional models may overlook. This innovative approach is designed to address emerging challenges in drug discovery, leveraging new scientific insights into biological pathways and disease mechanisms. Redesign Science aims to develop first-in-class small molecules targeting high unmet medical needs, thereby enhancing the efficiency of drug development processes and expanding the potential for therapeutic breakthroughs.

BioBin Data Science is an innovative agricultural high-tech enterprise focused on research and development in bioinformatics and plant breeding. The company specializes in creating advanced tools for plant breeding, including software and hardware solutions for data analysis, custom development, and strategic design. Its primary offering is a platform that analyzes test data and comparisons of various crop varieties, assisting breeders in evaluating characteristics such as stability and regional adaptability. This platform simplifies the reporting process, enabling users to generate comprehensive reports with a single click, thereby enhancing the efficiency and effectiveness of the breeding process.

MingSight Pharmaceuticals is focused on developing innovative ophthalmic drugs, particularly targeting diabetic retinopathy and related conditions. The company is conducting a clinical trial for its novel drug, MS-553, which represents the first clinical evaluation of this treatment for diabetic retinopathy. MS-553 is a highly selective protein kinase C (PKC) inhibitor that can be administered orally, offering a less invasive alternative to traditional intraocular injections, which can pose safety risks. In addition to its applications in diabetic retinopathy, MS-553 has shown promise in treating chronic lymphocytic leukemia (CLL) and diabetic macular edema (DME), demonstrating significant efficacy and market potential. The drug can be used alone or in combination with existing therapies, addressing specific mutations in patients and improving treatment outcomes.

Axbio Inc. is a biotechnology company based in Shenzhen, China, specializing in genetic sequencing technology and diagnostic solutions. Founded in 2016, the company develops a variety of products, including genome extraction kits for stool, blood, saliva, and bacteria. Axbio also provides advanced sequencing systems, disposable biochips, and reagents. The company is focused on creating high-throughput molecular diagnostics through its novel microfluidic Bio-CMOS platform, which supports both low-cost handheld devices for bedside diagnostics and fully automated laboratory instruments. This technology enables applications such as early cancer screening, rapid pathogen detection, and drug development. Currently, Axbio operates in stealth mode as it continues to innovate within the field.

Nafi Pharmaceuticals develops novel medications for central nervous system illnesses.

Ai Industry provides cosmetic product development and supply chain management services. They ensure the environmental sustainability of the overall solution and provide customers with real-time data on the end-to-end life cycle of the product.

Hongyun Biotech is a biotech company that promotes therapeutic innovation based on structural pharmacology.

HighlightLL Pharma is a pharmaceutical company focused on developing drugs for immune diseases and tumors. The company is dedicated to creating innovative product lines that possess global competitive advantages. By leveraging its unique pharmacological, biological, and clinical capabilities, HighlightLL Pharma aims to provide patients with safe and affordable treatment options.

Rgenta Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of RNA-targeting medicines with a primary focus on oncology and neurological disorders. Founded in 2018, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This platform enables the design of small-molecule compounds that modulate interactions among the spliceosome, regulatory proteins, and RNAs. By unlocking the therapeutic potential of previously undruggable targets, Rgenta aims to create oral, small-molecule therapies that address critical needs in human disease treatment, particularly in the realm of cancer.

BridGene Biosciences is a biotechnology company focused on discovering and developing small molecules aimed at traditionally untreatable targets. The company employs advanced chemoproteomic technology, integrating covalent chemistry, chemical proteomics, and quantitative mass spectrometry to create highly selective small-molecule inhibitors. This innovative approach allows for proteome-wide screening in live cells, facilitating the identification of drug targets that have historically been considered undruggable. By leveraging these techniques, BridGene seeks to advance therapeutic development in the healthcare sector, ultimately contributing to the discovery of new drugs and improving treatment options.

Elevoc is an AI-powered audio solution provider focused on enhancing voice communication through advanced technology. The company has developed a deep learning-based voice enhancement solution that operates in real time, allowing it to effectively extract speech from background noise and improve clarity and intelligibility. This innovative technology is utilized across millions of devices globally, catering to various industries including telecommunications, education, automotive, and security. Elevoc's offerings encompass a range of services such as intelligent noise reduction, echo cancellation, reverberation suppression, sound source localization, and beamforming, all aimed at facilitating superior voice signal processing and intelligent voice interaction.

PackGene Biotech, LLC is a biotechnology company based in the United States that specializes in developing viral vectors for gene therapies. It primarily focuses on adeno-associated virus (AAV) vectors, offering comprehensive services that include vector design, cloning, and packaging. The company also provides solutions for mRNA, plasmid DNA, and lentiviral vectors. With an emphasis on early-stage drug discovery and preclinical development, PackGene Biotech supports researchers in the medical industry by delivering high-purity, high-titer, and high-infectivity vectors for clinical applications. Its capabilities enable scalable and cost-effective production, facilitating advancements in cell and gene therapy trials.

Juncell Therapeutics focuses on developing innovative therapies and pharmaceutical drugs specifically for tumor treatment. The company specializes in tumor cell therapy, offering solutions to isolate tumor-infiltrating lymphocytes (TILs) from tumor tissues. These TILs are subsequently developed outside the human body and re-injected into patients, allowing for targeted treatment of tumors. This approach aims to enhance the effectiveness of cancer therapies while minimizing side effects, ultimately improving patient outcomes in the fight against cancer.

Teon Therapeutics is a clinical-stage biopharmaceutical company based in Redwood, California, founded in 2018. The company is focused on developing small molecule drugs aimed at cancer immunotherapy as well as addressing cardiovascular and metabolic diseases. Teon Therapeutics specializes in creating single-target small molecules that inhibit immunosuppressive and cancer-promoting signaling pathways within the tumor microenvironment. Its lead program involves an A2BR-specific antagonist, which is set to enter Phase 1b trials. By combining metabolic and GPCR immune checkpoint inhibitors, Teon aims to enhance the efficacy of immunotherapies, thereby improving long-term outcomes for cancer patients.

Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development.

Worg Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for allergies and other diseases with significant unmet medical needs. The company is constructing a robust pipeline targeting allergy and autoimmune disorders through two technology platforms, PCFiT and Apitope, leveraging both internal development and strategic collaborations. Additionally, Worg is advancing a platform for molecular allergy diagnosis, enhancing its capabilities in addressing allergy-related health issues. Through its flexible business models, Worg Pharmaceuticals aims to accelerate the development of effective immunotherapies and contribute to improved patient outcomes in the field of allergy and autoimmune diseases.

Quadriga BioSciences, Inc. is a pharmaceutical company based in Los Altos, California, founded in 2011, focused on developing proprietary targeted therapies for cancer treatment. The company's innovative approach is grounded in the understanding that many aggressive cancer cells possess unique amino acid transporters on their surfaces, which facilitate the intake of nutrients necessary for rapid tumor growth. By targeting these transporters, Quadriga BioSciences is creating novel therapeutic molecules aimed at selectively attacking cancer cells, thereby offering a more personalized and effective treatment option for patients. The ultimate goal of the company is to enhance the safety and efficacy of cancer therapies, addressing the urgent need for better treatment solutions in oncology.

Youxin Cloud is a cloud service provider specializing in Platform as a Service (PaaS) and Software as a Service (SaaS) solutions aimed at facilitating digital transformation for retail enterprises. The company offers a streamlined approach that enables businesses to develop, utilize, and manage applications without the burden of complex IT infrastructure. By employing advanced technologies, Youxin Cloud delivers tailored customer relationship management (CRM) services that integrate various levels of the retail chain, from management teams to customers. This integration allows clients to access real-time insights into their business operations across multiple interfaces, empowering them to make informed decisions efficiently.

AcroImmune is a biotechnology company focused on the development of immunotherapy drugs aimed at treating malignant tumors and inflammatory diseases. The company is dedicated to creating both first-in-class and best-in-class therapeutic options for patients suffering from these conditions. By leveraging innovative approaches in immunotherapy, AcroImmune seeks to provide effective treatment alternatives for individuals affected by tumors and related inflammatory disorders.

Oxford BioTherapeutics Ltd is a biotechnology company specializing in the development of targeted antibody-drug conjugates for cancer treatment. Utilizing its proprietary OGAP platform, which is one of the largest human protein databases, the company identifies a range of validated and novel antigen targets from various cancer types. Its leading product, OBT076, is an antibody-drug conjugate aimed at treating high-risk HER2 negative breast cancer, as well as other solid tumors such as gastric, lung, bladder, and ovarian cancers. In addition to its cancer therapies, Oxford BioTherapeutics is also engaged in developing antibody-based treatments for acute myeloid leukemia. The company has formed strategic collaborations with prominent antibody firms to enhance its pipeline of novel therapeutics. Established in 2003 and based in Oxon, United Kingdom, with a presence in San Jose, California, Oxford BioTherapeutics aims to improve patient outcomes through innovative treatments and the integration of companion diagnostics into its development processes.

ONL Therapeutics is a biopharmaceutical company focused on developing innovative therapeutics to protect and improve vision in patients with retinal diseases and conditions. Founded in 2006 and headquartered in Ann Arbor, Michigan, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway. Its drug programs aim to safeguard photoreceptors, thereby enhancing outcomes for patients undergoing surgeries related to retinal detachment and other serious vision-threatening issues. Through its research and development efforts, ONL Therapeutics seeks to provide effective solutions for preserving sight and improving the quality of life for individuals affected by these conditions.

Totient Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2016. It specializes in data analysis for drug discovery and development, focusing on identifying novel tissue-specific antigens using tertiary lymphoid structures (TLSs). The company employs advanced machine learning and immunoinformatics to extract valuable insights from large datasets, facilitating the rapid assembly of high-affinity antibody candidates. Totient's platform is versatile, enabling the development of therapeutics aimed at treating cancer, autoimmune diseases, infections, and viral conditions. By leveraging knowledge from recent research and patient-derived tissues with exceptional immune responses, Totient aims to deliver effective antibody therapeutics for a range of medical applications.

OncoImmune, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for cancer and autoimmune diseases. The company's portfolio features several key candidates, including CD24Fc, a recombinant fusion protein aimed at preventing acute graft versus host disease in leukemia patients undergoing hematopoietic stem cell transplantation. OncoImmune has completed a Phase II clinical trial for CD24Fc and is preparing to initiate a pivotal trial for this indication. Additionally, the company is developing sialidase inhibitors to prevent sepsis, ONC-392, a monoclonal antibody that minimizes immune-related toxicities while maintaining anti-tumor activity, and Echinomycin, a formulation for treating acute myeloid leukemia. Founded in 2000, OncoImmune is headquartered in Rockville, Maryland.

Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases.

Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development.

Atom Bioscience is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory and metabolic diseases. The company concentrates on addressing conditions such as chronic gout, non-alcoholic steatohepatitis, diabetes, and colon cancers. By targeting the underlying mechanisms of metabolism and inflammation, Atom Bioscience aims to provide patients with more effective treatment options for these complex health issues.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Yunying Medical specializes in gene mutation, methylation detection, and recombination solutions for cancer diagnosis and treatment.

Rgenta Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of RNA-targeting medicines with a primary focus on oncology and neurological disorders. Founded in 2018, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This platform enables the design of small-molecule compounds that modulate interactions among the spliceosome, regulatory proteins, and RNAs. By unlocking the therapeutic potential of previously undruggable targets, Rgenta aims to create oral, small-molecule therapies that address critical needs in human disease treatment, particularly in the realm of cancer.

Asieris Pharmaceuticals Co. Ltd. is a Chinese biotechnology company established in 2010, headquartered in Taizhou, China. The company specializes in the research and development of pharmaceutical products aimed at treating tumors and addressing multidrug-resistant infections. Asieris is committed to advancing therapeutic solutions that integrate both diagnosis and treatment, catering to the needs of patients in China and globally. Through its innovative approach, the company seeks to contribute significantly to the fields of oncology and infectious disease management.

F&S Pharmatech is a pharmaceutical technology company based in Nanjing, China. The company specializes in the development of differentiated generic drugs and pharmaceutical intermediates, focusing on advanced pharmaceutical chemicals. Its product offerings include key intermediates such as sacubitril and diphenyl piperidine methanol, aimed at supporting research and development centers as well as generic drug developers. F&S Pharmatech also provides contract manufacturing organization (CMO) services and offers intellectual property solutions alongside environmentally friendly chemical technologies. By prioritizing innovation and efficiency, the company seeks to shorten development cycles and reduce costs for customers in the healthcare industry.

Mockplus is a web-based collaborative design platform that facilitates the design process for teams of designers, product managers, and developers. The platform offers tools for prototyping, importing designs from various mainstream design applications, and managing projects and design systems in a cohesive manner. Mockplus includes three primary tools: Mockplus Classic, Mockplus RP, and Mockplus Cloud, all designed to enhance workflow efficiency and promote seamless online collaboration. By simplifying design tasks, Mockplus enables teams to work together more effectively and finalize projects with greater speed and ease.

Sansong Medical Group provides building construction, industry resource integration, and mergers and acquisitions of nephrology hospitals.

Aoquan is a biopharmaceutical company that provides research and development, production, and industrialization of innovative drugs.

Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development.

Amphivena Therapeutics is a clinical-stage immuno-oncology company focused on developing bifunctional antibody therapies aimed at treating hematologic malignancies. Founded in 2012 and based in South San Francisco, California, the company utilizes its proprietary ReSTORE platform to create dual-action biologics that enhance the patient's immune response against cancer. These therapies are designed to relieve immune suppression while activating T cells, thereby promoting the destruction of tumor cells and their precursors. The platform emphasizes avidity, target selectivity, and safety, and can be engineered to include additional functionalities for targeting solid tumors. As a subsidiary of Affimed N.V., Amphivena Therapeutics aims to provide innovative treatment options for patients facing blood cancers.

iLabService specializes in laboratory monitoring, management, and automation services through the application of Internet of Things (IoT) and artificial intelligence (AI) technologies. Founded in 2016 and headquartered in Shanghai, China, with additional offices in Hangzhou, Silicon Valley, and New Jersey, the company offers subscription-based monitoring services tailored for biotechnology and pharmaceutical laboratories. Its flagship product, the INTELAB DAQ, is a sensor-based device that monitors lab equipment, providing alerts to technicians when issues arise. Additionally, iLabService develops software that analyzes lab data, transforming it into actionable insights to enhance operational efficiency. By integrating various laboratory needs—including preventive maintenance optimization, asset utilization, and chemical management—into a single platform, iLabService helps laboratory managers streamline operations and reduce costs.

PackGene Biotech, LLC is a biotechnology company based in the United States that specializes in developing viral vectors for gene therapies. It primarily focuses on adeno-associated virus (AAV) vectors, offering comprehensive services that include vector design, cloning, and packaging. The company also provides solutions for mRNA, plasmid DNA, and lentiviral vectors. With an emphasis on early-stage drug discovery and preclinical development, PackGene Biotech supports researchers in the medical industry by delivering high-purity, high-titer, and high-infectivity vectors for clinical applications. Its capabilities enable scalable and cost-effective production, facilitating advancements in cell and gene therapy trials.

Forkhead BioTherapeutics Inc is focused on developing innovative oral therapies for insulin-dependent diabetes. Based in New York, the company has created Foxin, an oral agent designed to target and delete the FOXO1 protein, which plays a crucial role in regulating insulin production and glucose metabolism. Founded in 2017, Forkhead Bio aims to harness the natural processes of cell conversion and regeneration to create transformative treatments that enhance the quality of life for patients with diabetes.

Sorghum Pharmaceuticals develops small molecule targeted innovative drugs for the unmet medical needs of autoimmune diseases and tumors. In the direction of unmet medical needs in autoimmune diseases and tumors, Gaochun Pharmaceuticals is committed to creating innovative product lines with global competitive advantages by leveraging its distinctive pharmaceutical, biological and clinical capabilities.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Zhejiang Daoer Biotechnology Co., Ltd. is a scientific research biopharmaceutical company based in the Xiasha Economic Development Zone of Hangzhou, Zhejiang Province. The company specializes in the development and research of protein drugs aimed at treating metabolic diseases, ophthalmological conditions, and cancer. Utilizing an innovative platform known as xLONGylation, which is a recombinant PEG-like polypeptide, Doer Biologics enhances drug targeting and safety. This advanced technology also supports the creation of activated antibodies for precision tumor therapy and multi-targeted biotherapeutics, facilitating the design of effective treatments for various diseases.

Wangbaoba is a oatmeal brand, and consumers can buy it through some shopping platforms

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.